Methods of treating lung cancer
AssigneeFive Prime Therapeutics, Inc.
InventorsThomas Harding, Servando Palencia, Li Long, Kevin Hestir
Life of this patent
Estimating the term…
Abstract
Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
Claims20
A method of treating lung cancer having a fibroblast growth factor receptor 1 (FGFR1) gene amplification in a subject, wherein at least a portion of the cells of the lung cancer having an FGFR1 gene amplification have a ratio of FGFR1 gene to chromosome 8 centromere of at least 1.5, comprising:
- administering a therapeutically effective amount of an FGFR1 extracellular domain (ECD) or an FGFR1 ECD fusion molecule to the subject.
A method of treating lung cancer having a fibroblast growth factor receptor 1 (FGFR1) gene amplification in a subject, comprising administering a therapeutically effective amount of an FGFR1 extracellular domain (ECD) or an FGFR1 ECD fusion molecule to the subject, wherein, prior to administration of the FGFR1 ECD or FGFR1 ECD fusion molecule, at least a portion of the cells of the lung cancer have been determined to have a ratio of FGFR1 gene to chromosome 8 centromere of at least 1.5.
A method of treating non-small cell lung cancer (NSCLC) having a fibroblast growth factor receptor (FGFR1) gene amplification in a subject, wherein at least a portion of the cells of the cancer having an FGFR1 gene amplification have a ratio of FGFR1 gene to chromosome 8 centromere of at least 1.5, comprising:
- administering a therapeutically effective amount of an FGFR1 extracellular domain (ECD) fusion molecule comprising the amino acid sequence of SEQ ID NO:
- 6, paclitaxel, and carboplatin to the subject.
Dependencies are inferred from the claim text.